GlassScriptPhysician profile
Crystal Kirby
NPI 1003564725
$2,334.33
in general payments reported to CMS, 2019-2025
28 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,226 · 2023: $554 · 2024: $275 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.66 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.97 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $184.82 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $153.09 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $134.29 | 2022-2025 | Fanapt |
| Alkermes, INC. | $122.27 | 2022-2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $89.29 | 2022 | |
| Lundbeck LLC | $85.12 | 2022-2023 | Brintellix, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $72.59 | 2022 | |
| Banner Life Sciences, LLC | $63.83 | 2022 | |
| Lilly USA, LLC | $60.48 | 2022 | |
| Neurocrine Biosciences, INC. | $59.31 | 2022-2023 | Ingrezza |
| Corium, LLC | $54.31 | 2024-2025 | Azstarys |
| Acadia Pharmaceuticals INC | $39.88 | 2022 | |
| Emd Serono, INC. | $39.08 | 2022-2023 | Mavenclad |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $38.10 | 2022-2023 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $37.90 | 2022 | |
| Supernus Pharmaceuticals, INC. | $31.89 | 2022 | |
| Argenx US, INC. | $24.67 | 2022 | |
| Csl Behring | $20.87 | 2022 | |
| Avion Pharmaceuticals | $20.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.43 | 2023 | Spravato |
| Tris Pharma INC | $17.98 | 2023 | Dyanavel Xr |
| Sk Life Science, INC. | $16.98 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.82 | 2022 | |
| Eisai INC. | $16.64 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $14.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.73 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.